Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Prostate. 2012 Dec 19;73(7):677–689. doi: 10.1002/pros.22608

FIGURE 7.

FIGURE 7

Comparison of the cost effectiveness of achieving 80% power by performing genotyping plus imputation to the cost effectiveness of sequencing. Above calculations are for a hypothetical disease with prevalence 10%, per allele relative risk of 1.3, and alpha of 5×10−8. A genotyping to sequencing ratio greater than one indicates a scenario where it is more cost effective to sequence. Three scenarios of relative pricing are considered. The genotyping to sequencing ratio is plotted on a logarithmic scale.